Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT) and long‐term extension study
Sign Up to like & getrecommendations! Published in 2020 at "European Journal of Heart Failure"
DOI: 10.1002/ejhf.2027
Abstract: Tafamidis is an effective treatment for transthyretin amyloid cardiomyopathy (ATTR‐CM) in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT). While ATTR‐ACT was not designed for a dose‐specific assessment, further analysis from ATTR‐ACT and its long‐term… read more here.
Keywords: attr act; attr; tafamidis transthyretin; transthyretin cardiomyopathy ... See more keywords
Systemic embolism in amyloid transthyretin cardiomyopathy
Sign Up to like & getrecommendations! Published in 2022 at "European Journal of Heart Failure"
DOI: 10.1002/ejhf.2566
Abstract: Although systemic embolism is a potential complication in transthyretin amyloid cardiomyopathy (ATTR‐CM), data about its incidence and prevalence are scarce. We studied the incidence, prevalence and factors associated with embolic events in ATTR‐CM. Additionally, we… read more here.
Keywords: systemic embolism; amyloid transthyretin; embolism amyloid; embolism ... See more keywords
Left ventricular hypertrophy, dilatation and ejection fractions predict ventricular tachycardia in amyloid transthyretin cardiomyopathy
Sign Up to like & getrecommendations! Published in 2023 at "Europace"
DOI: 10.1093/europace/euad122.274
Abstract: Abstract Funding Acknowledgements Type of funding sources: Private company. Main funding source(s): Pfizer Global Medical Grant Background Amyloid transthyretin cardiomyopathy (ATTR-CM) is a progressive infiltrative cardiomyopathy caused by extracellular deposition of amyloid fibrils. The disease… read more here.
Keywords: ventricular tachycardias; amyloid transthyretin; ventricular tachycardia; transthyretin cardiomyopathy ... See more keywords